Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 1, 2013, Pages 97-111

  Himmel, Herbert M ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Beating rate; Contraction; Impedance method; In vitro; Ion channel modulators; Stem cell derived cardiomyocytes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; A 0981; ARSENIC TRIOXIDE; DIMETHYL SULFOXIDE; DOFETILIDE; N 7634; N [3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL] N METHYLMETHANESULFONAMIDE; NIFEDIPINE; O 3125; OUABAIN; P 0547; PENTAMIDINE; POTASSIUM CHANNEL HERG; PZ 0016; SEA ANEMONE TOXIN; SODIUM CHANNEL NAV1.5; TETRODOTOXIN; UNCLASSIFIED DRUG; V 4629; VERAPAMIL;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOXICITY; HEART BEAT; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMPEDANCE; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LABORATORY DEVICE; MOUSE; MUSCLE CONTRACTION; NONHUMAN; PLURIPOTENT STEM CELL; SCREENING TEST; STEADY STATE; STEM CELL;

ACTION POTENTIAL; ANEMONIA SULCATA TOXIN 2; AP; AP DURATION; APD; ATX-II; BEATING RATE; CONTRACTION; DIMETHYLSULFOXIDE; DMSO; ECG; ELECTROCARDIOGRAM; EMBRYONIC STEM CELL; ESC; FIELD POTENTIAL; FP; FP DURATION; FPD; HEK; HERG; HUMAN EMBRYONIC KIDNEY; HUMAN ETHER-A-GO-GO-RELATED GENE; I(CA.L); I(NA); IMPEDANCE METHOD; IN-VITRO; INDUCED PLURIPOTENT STEM CELL; ION CHANNEL MODULATORS; IPSC; L-TYPE CA(2+) CURRENT; NA(+) CURRENT; PAPILLARY MUSCLE; PF; PM; PURKINJE FIBER; REAL-TIME CELLULAR ANALYZER; RTCA; SC-CM; STEM CELL-DERIVED CARDIOMYOCYTES;

ANIMALS; DIMETHYL SULFOXIDE; ELECTRIC IMPEDANCE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; REPRODUCIBILITY OF RESULTS; SOLVENTS; SPECIES SPECIFICITY; TIME FACTORS; TOXICITY TESTS;

STROPHANTHUS GRATUS;

EID: 84880038308     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.05.005     Document Type: Article

References (101)

1. Abassi Y.A., Xi B., Li N., Ouyang W., Seiler A., Watzele M., et al. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. British Journal of Pharmacology 2012, 165:1424-1441.
2. Ks, β-adrenoceptor stimulation, pacing rate and gender. British Journal of Pharmacology 2006, 147:653-660.
3. Abrahamsson C., Duker G., Lundberg C., Carlsson L. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: A comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovascular Research 1993, 27:861-867.
4. Agostoni P.G., De Cesare N., Doria E., Polese A., Tamborini G., Guazzi M.D. Afterload reduction: A comparison of captopril and nifedipine in dilated cardiomyopathy. British Heart Journal 1986, 55:391-399.
5. Alsen C. Biological significance of peptides from Anemonia sulcata. Federation Proceedings 1983, 42:101-108.
6. Anonymous ICH S7A: Safety pharmacology studies for human pharmaceuticals (CPMP/ICH/539/00) (accessed on 16 Jan 2013). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf.
7. Anonymous ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. CHMP/ICH/423/02 (accessed on 16 Jan 2013). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf.
8. Aomine M. Tetrodotoxin-sensitive potential plateau of fibers: Comparison with component in action guinea pig purkinje the papillary muscle. General Pharmacology 1989, 20:791-797.
9. Baer M., Best P.M., Reuter H. Voltage-dependent action of tetrodotoxin in mammalian cardiac muscle. Nature 1976, 263:344-345.
10. Baskin E.P., Serik C.M., Wallace A.A., Brookes L.M., Selnick H.G., Claremon D.A., et al. Effects of new and potent methanesulfonanilide class-3 antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. Journal of Cardiovascular Pharmacology 1991, 18:406-414.
11. Bosch R.F., Schneck A.C., Csillag S., Eigenberger B., Gerlach U., Brendel J., et al. Effects of the chromanol HMR 1556 on potassium currents in atrial myocytes. Naunyn-Schmiedeberg's Archives of Pharmacology 2003, 367:281-288.
12. Bouchard R.A., Clark R.B., Giles W.R. Regulation of unloaded cell shortening by sarcolemmal sodium-calcium exchange in isolated rat ventricular myocytes. The Journal of Physiology 1993, 469:583-599.
13. Braam S.R., Tertoolen L., van de Stolpe A., Meyer T., Passier R., Mummery C.L. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Research 2010, 4:107-116.
14. Carmeliet E. Voltage-dependent block by tetrodotoxin of the sodium channel in rabbit cardiac Purkinje fibers. Biophysical Journal 1987, 51:109-114.
15. Chahine M., Plante E., Kallen R.G. Sea anemone toxin (ATX II) modulation of heart and skeletal muscle sodium channel α-subunits expressed in tsa201 cells. Journal of Membrane Biology 1996, 152:39-48.
16. Chui R.W., Fosdick A., Conner R., Jiang J., Bruenner B.A., Vargas H.M. Assessment of two external telemetry systems (PhysioJacket™ and JET™) in beagle dogs with telemetry implants. Journal of Pharmacological and Toxicological Methods 2009, 60:58-68.
17. Cohen J.D., Babiarz J.E., Abrams R.M., Guo L., Kameoka S., Chiao E., et al. Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicology and Applied Pharmacology 2011, 257:74-83.
18. Cohen C.J., Bean B.P., Colatsky T.J., Tsien R.W. Tetrodotoxin block of sodium channels in rabbit Purkinje fibers. Interactions between toxin binding and channel gating. Journal of General Physiology 1981, 78:383-411.
19. Cordes J.S., Sun Z., Lloyd D.B., Bradley J.A., Opsahl A.C., Tengowski M.W., et al. Pentamidine reduces hERG expression to prolong the QT interval. British Journal of Pharmacology 2005, 145:15-23.
20. Davie C., Valentin J.P., Pollard C., Standen N., Mitcheson J., Alexander P., et al. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (IKr) channel. Journal of Cardiovascular Electrophysiology 2004, 15:1302-1309.
21. Denning C., Anderson D. Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discovery Today 2008, 5:223-232.
22. Dennis A.T., Wang L., Wan H., Nassal D., Deschenes I., Ficker E. Molecular determinants of pentamidine-induced hERG trafficking inhibition. Molecular Pharmacology 2012, 81:198-209.
23. Doggrell S.A., Nand V., Henderson C.J. The effects of lignocaine and tetrodotoxin on the action potentials and contractions of left ventricles from normo- and hypertensive rats. General Pharmacology 1999, 32:429-437.
24. Dumotier B.M., Adamantidis M.M., Puisieux F.L., Bastide M.M., Dupuis B.A. Repercussions of pharmacologic reduction in ionic currents on action potential configuration in rabbit Purkinje fibers: Are they indicative of proarrhythmic potential?. Drug Development Research 1999, 47:63-76.
25. Dunlop J., Bowlby M., Peri R., Vasilyev D., Arias R. High-throughput electrophysiology: An emerging paradigm for ion channel screening and physiology. Nature Reviews Drug Discovery 2008, 7:358-368.
26. Echizen H., Manz M., Eichelbaum M. Electrophysiologic effects of dextro- and levo-verapamil on sinus node and AV node function in humans. Journal of Cardiovascular Pharmacology 1988, 12:543-546.
27. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews Drug Discovery 2003, 2:439-447.
28. Force T., Kolaja K.L. Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes. Nature Reviews 2011, 10:111-126.
29. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews. Cancer 2007, 7:332-344.
30. Fujiki A., Tani M., Mizumaki K., Shimono M., Inoue H. Electrophysiologic effects of intravenous E-4031, a novel class-3 antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. Journal of Cardiovascular Pharmacology 1994, 23:374-378.
31. Gao B.X., Qu Y., Mei F., Vargas H.M. Contractility measurement in rat heart: Comparison of isolated myocytes and Langendorff-perfused whole heart. SPS Annual Meeting 2012, poster no. 96 2012.
32. Gögelein H., Brüggemann A., Gerlach U., Brendel J., Busch A.E. Inhibition of IKs channels by HMR 1556. Naunyn-Schmiedeberg's Archives of Pharmacology 2000, 362:480-488.
33. Grskovic M., Javaherian A., Strulovici B., Daley G.Q. Induced pluripotent stem cells - Opportunities for disease modelling and drug discovery. Nature Reviews Drug Discovery 2011, 10:915-929.
34. Guo L., Abrams R., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., et al. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell derived cardiomyocytes. Toxicological Sciences 2011, 123:281-289.
35. Guo L., Qian J.Y., Abrams R., Tang H.M., Weiser T., Sanders M.J., et al. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts. Cell Physiology and Biochemistry 2011, 27:453-462.
36. Gwilt M., Arrowsmith J.E., Blackburn K.J., Burges R.A., Cross P.E., Dalrymple H.W., et al. UK68,798: A novel, potent and highly selective class-3 antiarrhythmic agent which blocks potassium channels in cardiac cells. Journal of Pharmacology and Experimental Therapeutics 1991, 256:318-324.
37. Hancox J.C., Curtis M.J. Preparation, preparation, preparation: The influence of adrenergic agonism in cardiac ventricular repolarisation assays used in preclinical drug development and drug safety pharmacology. Journal of Pharmacological and Toxicological Methods 2005, 51:77-79.
38. Hansen A., Eder A., Bönstrup M., Flato M., Mewe M., Schaaf S., et al. Development of a drug screening platform based on engineered heart tissue. Circulation Research 2010, 107:35-44.
39. Harding S.E., Ali N.N., Brito-Martins M., Gorelik J. The human embryonic stem cell-derived cardiomyocyte as a pharmacological model. Pharmacology and Therapeutics 2007, 113:341-353.
40. Harmer A.R., Abi-Gerges N., Morton M.J., Pullen G.F., Valentin J.P., Pollard C.E. Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicology and Applied Pharmacology 2012, 260:162-172.
41. Harris K., Sridhar A. Comparison of electrophysiological data from human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) to current pre-clinical safety assays: an integrated GSK experience. SPS Annual Meeting 2012, poster no. 77 2012.
42. Hasinoff B.B. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicology and Applied Pharmacology 2010, 244:190-195.
43. Himmel H.M. Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential. Journal of Pharmacological and Toxicological Methods 2007, 56:145-158.
44. Himmel H.M., Bussek A., Hoffmann M., Beckmann R., Lohmann H., Schmidt M., et al. Field and action potential recordings in heart slices: correlation with established in vitro and in vivo models. British Journal of Pharmacology 2012, 166:276-296.
45. Hoey A., Harrison S.M., Boyett M.R., Ravens U. Effects of the anemonia sulcata toxin (ATX II) on intracellular sodium and contractility in rat and guinea-pig myocardium. Pharmacology & Toxicology 1994, 75:356-365.
46. Isenberg G., Ravens U. The effects of the anemonia sulcata toxin (ATX II) on membrane currents of isolated mammalian myocytes. The Journal of Physiology 1984, 357:127-149.
47. Jakob H., Nawrath H. Tetrodotoxin slightly shortens action potential duration in ventricular but not in atrial heart muscle. Experientia 1988, 44:16-17.
48. Johnson D.M., Geys R., Lissens J., Guns P.J. Drug-induced effects on cardiovascular function in pentobarbital anesthetized guinea-pigs: Invasive LVP measurements versus the QA interval. Journal of Pharmacological and Toxicological Methods 2012, 66:152-159.
49. Johnson B.D., Hockerman G.H., Scheuer T., Catterall W.A. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines. Molecular Pharmacology 1996, 50:1388-1400.
50. Jonsson M.K.B., Vos M.A., Mirams G.R., Duker G., Sartipy P., de Boer T.P., et al. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. Journal of Molecular and Cellular Cardiology 2012, 52:998-1008.
51. Jonsson M.K.B., Wang Q.D., Becker B. Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay and Drug Development Technologies 2011, 9:589-599.
52. Ju Y.K., Saint D.A., Gage P.W. Tetrodotoxin-sensitive inactivation-resistant sodium channels in pacemaker cells influence heart rate. Pflügers Archives 1996, 431:868-875.
53. 2+ channel pharmacology between native and stem cell-derived cardiomyocytes. Journal of Pharmacology and Experimental Therapeutics 2012, 341:510-517.
54. Katchman A.N., Koerner J., Tosaka T., Woosley R.L., Ebert S.N. Comparative evaluation of hERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. Journal of Pharmacology and Experimental Therapeutics 2006, 316:1098-1106.
55. Katritsis D., Morgan J., Brachmann J., Bygrave A., O'Earrell D., Rowland E., et al. Electrophysiological effects of E-4031, a drug with selective class-3 properties, in man. PACE 1997, 20:930-937.
56. Kattman S.J., Koonce C.H., Swanson B.J., Anson B.D. Stem cells and their derivatives: a renaissance in cardiovascular translational research. Journal of Cardiovascular Translational Research 2011, 4:66-72.
57. Ke N., Wang X., Xu X., Abassi Y.A. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods in Cell Biology 2011, 740:33-43.
58. Kettenhofen R., Tressat K., Kolossov E., Jähne E., Hebeisen S., Ehlich A., et al. In vitro pharmacology and safety testing using human iPS-derived Cor.4U cardiomyocytes. SPS Annual Meeting 2012, poster no. 23 2012.
59. Knilans T.K., Lathrop D.A., Nanasi P.P., Schwartz A., Varro A. Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and Vmax. British Journal of Pharmacology 1991, 103:1568-1572.
60. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. Journal of Pharmacology and Experimental Therapeutics 2005, 312:316-323.
61. Lawrence C.L., Pollard C.E., Hammond T.G., Valentin J.P. In vitro models of proarrhythmia. British Journal of Pharmacology 2008, 154:1516-1522.
62. Lee Y.K., Ng K.M., Lai W.H., Chan Y.C., Lau Y.M., Lian Q., et al. Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Reviews & Reports 2011, 7:976-986.
63. Lin T.C., Wie J., Yeh T.C., Lin C.I. Effects of tetrodotoxin on action potentials in myocardium obtained from patients with heart failure. New Trends in Arrhythmias 1993, 9:27-31.
64. Ks channel blockers in vitro. Journal of Pharmacological and Toxicological Methods 2005, 51:81-90.
65. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. American Journal of Physiology 2011, 301:H2006-H2017.
66. Mandenius C.F., Steel D., Noor F., Meyer T., Heinzle E., Asp J., et al. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review. Journal of Applied Toxicology 2011, 31:191-205.
67. 2+ channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart. General Pharmacology 1991, 22:87-91.
68. Mellor H.R., Bell A.R., Valentin J.P., Roberts R.R. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicological Sciences 2011, 120:14-32.
69. Nawrath H., Wegener J.W. Kinetics and state-dependent effects of verapamil on cardiac L-type calcium channels. Naunyn-Schmiedeberg's Archives of Pharmacology 1997, 355:79-86.
70. Peng S., Lacerda A.E., Kirsch G.E., Brown A.M., Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. Journal of Pharmacological and Toxicological Methods 2010, 61:277-286.
71. Pouton C.W., Haynes J.M. Embryonic stem cells as a source of models for drug discovery. Nature Reviews Drug Discovery 2007, 6:605-616.
72. Qu Y., Fang M., Gao B.X., Chui R.W., Vargas H.M. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart. Journal of Pharmacology and Experimental Therapeutics 2011, 337:2-8.
73. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
74. Reppel M., Igelmund P., Egert U., Juchelka F., Hescheler J., Drobinskaya I. Effect of cardioactive drugs on action potential generation and propagation in embryonic stem cell-derived cardiornyocytes. Cell Physiology and Biochemistry 2007, 19:213-224.
75. Ritchie R.H., Zeitz C.J., Wuttke R.D., Hii J.T., Horowitz J.D. Attenuation of the negative inotropic effects of metoprolol at short cycle lengths in humans: comparison with sotalol and verapamil. Journal of the American College of Cardiology 2006, 48:1234-1241.
76. Roden D.M. Drug-induced prolongation of the QT interval. The New England Journal of Medicine 2004, 350:1013-1022.
77. Rousseau M.F., Massart P.E., van Eyll C., Etienne J., Ahn S., Ghadanfar M., et al. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. The American Journal of Cardiology 2001, 87:1250-1254.
78. Sasayama S. Inotropic agents in the treatment of heart failure: despair or hope?. Cardiovascular Drugs & Therapeutics 1997, 10:703-709.
79. Satin J., Kyle J.W., Chen M., Bell P., Cribbs L.L., Fozzard H.A., et al. A mutant of TTX-resistant cardiac sodium channels with TTX-sensitive properties. Science 1992, 256:1202-1205.
80. Scheel O., Himmel H.M., Rascher-Eggstein G., Knott T. Introduction of a modular automated voltage-clamp platform and its correlation with manual human ether-a-go-go related gene voltage-clamp data. Assay and Drug Development Technologies 2011, 9:600-607.
81. Schwinger R.H., Böhm M., Erdmann E. Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardial tissue. Journal of Cardiovascular Pharmacology 1990, 15:892-899.
82. Sensch O., Vierling W., Brandt W., Reiter M. Effects of inhibition of calcium and potassium currents in guinea-pig cardiac contraction: comparison of beta-caryophyllene oxide, eugenol, and nifedipine. British Journal of Pharmacology 2000, 131:1089-1096.
83. Shah R.R. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Safety 2005, 28:115-125.
84. So P.P.S., Hu X.D., Backx P.H., Puglisi J.L., Dorian P. Blockade of IKs by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles. British Journal of Pharmacology 2006, 148:255-263.
85. Stern H.C., Matthews J.H., Belz G.G. Intrinsic and reflex actions of verapamil and nifedipine: assessment in normal subjects by noninvasive techniques and autonomic blockade. European Journal of Clinical Pharmacology 1986, 29:541-547.
86. Synnergren J., Améen C., Jansson A., Sartipy P. Global transcriptional profiling reveals similarities and differences between human stem cell-derived cardiomyocyte clusters and heart tissue. Physiology & Genomics 2012, 44:245-258.
87. Tanaka H., Masumiya H., Sekine T., Sijuku T., Sugahara M., Taniguchi H., et al. Myocardial and vascular effects of efonidipine in vitro as compared with nifedipine, verapamil and diltiazem. General Pharmacology 1996, 27:451-454.
88. Tande P.M., Björnstad H., Yang T., Refsum H. Rate-dependent class-3 antiarrhythmic action, negative chronotropy, and positive inotropy of a novel IK blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. Journal of Cardiovascular Pharmacology 1990, 16:401-410.
89. Uehara A., Hume J.R. Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells. Journal of General Physiology 1985, 85:621-647.
90. Wallace A.A., Stupienski R.F., Brookes L.M., Selnick H.G., Claremon D.A., Lynch J.J. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class-3 antiarrhythmic agents in anesthetized dogs. Journal of Cardiovascular Pharmacology 1991, 18:687-695.
91. Wang X.L., Hua Z., Zhang Y. Effect of potassium channel blockers on isolated rat atrium. Drug Development Research 1996, 39:161-166.
92. Ks potassium channel in human embryonic stem cell-derived myocytes. Pediatric Cardiology 2012, 33:938-942.
93. Wasserstrom J.A., Salata J.J. Basis for tetrodotoxin and lidocaine effects on action potentials in dog ventricular myocytes. American Journal of Physiology 1988, 254:H1157-H1166.
94. Webster R., Allan G., Anto-Awuakye K., Harrison A., Kidd T., Leishman D., et al. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica 2001, 31:633-650.
95. Wettwer E., Scholtysik G., Schaad A., Himmel H.M., Ravens U. Effects of the new class-3 antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. Journal of Cardiovascular Pharmacology 1991, 17:480-487.
96. Xi J., Khalil M., Shishechian N., Hannes T., Pfannkuche K., Liang H., et al. Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. The FASEB Journal 2010, 24:2739-2751.
97. Xi B., Wang T., Li N., Ouyang W., Zhang W., Wu J., et al. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA cardio system. Journal of Laboratory Automation 2011, 16:415-421.
98. Yamazaki K., Hihara T., Taniguchi T., Kohmura N., Yoshinaga T., Ito M., et al. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. Toxicology in Vitro 2012, 26:335-342.
99. Yokoyama H., Nakamura Y., Iwasaki H., Nagayama Y., Hoshiai K., Mitsumori Y., et al. Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs. Journal of Pharmacological Sciences 2009, 110:476-482.
100. 2+ exchange. Cardiovascular Drugs & Therapeutics 2009, 23:207-214.
101. Zhang S., Zhou Z.F., Gong Q., Makielski J.C., January C.T. Mechanism of block and identification of the verapamil binding domain to hERG potassium channels. Circulation Research 1999, 84:989-998.